

Carl Salzman Curriculum Vitae: January 2023

Education

1959 B.S.	Union College, Schenectady, NY
1963 M.D. Syracuse, NY	State University of New York, Upstate Medical Center,
1993 M.A. (Hon)	Harvard University, Cambridge, MA

Postdoctoral Training:

Internship and Residencies:

1963-1964	Internship in Pediatrics, St. Luke's Hospital, New York City
1964-1967	Resident in Psychiatry, Massachusetts Mental Health Center, Boston
1967-1968	Student (postgraduate), Foundation for Advanced Education in the Sciences, NIH.

Licensure and Certification

1969-	Massachusetts License
1970-	American Board of Psychiatry and Neurology (Psychiatry)

Academic Appointments

1964-1967	Teaching Fellow in Psychiatry, Harvard Medical School
1969-1970	Instructor in Psychiatry at the Massachusetts Mental Health Center, Harvard Medical School
1970-1979	Assistant Professor of Psychiatry at the Massachusetts Mental Health Center, Harvard Medical School
1979-1993	Associate Professor of Psychiatry at the Massachusetts Mental Health Center, Harvard Medical School
1993-Present	Professor of Psychiatry, Harvard Medical School, at the Massachusetts Mental Health Center

Hospital Appointments

1966-1967	Consultant in Psychiatry, Faulkner Hospital, Boston
1966-1967	Consultant in Psychiatry, Phillips Brooks House, Harvard University
1967-1969	Consultant in Psychiatry, NIMH Mental Health Study Center, Adelphi, Maryland
1969-1970	Research Consultant in Psychiatry, Patuxent Institution, Jessup, Maryland
1973-	Assistant Psychiatrist, Beth Israel Hospital
1973-	Assistant Psychiatrist, McLean

1983-1986 Psychiatric Staff, Hahnemann Hospital
 1985-1986 Psychiatric Staff, Brockton VA Hospital

Principal Clinical and Hospital Service Responsibilities

1969-1970 Senior Psychiatrist, Massachusetts Mental Health Center
 1970-1980 Staff Psychiatrist, Massachusetts Mental Health Center
 1970-1979 Co-Director, Psychopharmacology Research Laboratory, Harvard Medical School, Massachusetts Mental Health Center
 1970-1974 Assistant Clinical Director, Southard Clinic, Massachusetts Mental Health Center
 1975- Chairman, Pharmacy Committee, Massachusetts Mental Health Center
 1978-1979 President, Medical Staff, Massachusetts Mental Health Center
 1980- Psychiatrist III, Massachusetts Mental Health Center
 1974-1979 Associate Director of Inpatient Services, (Day Hospital), Massachusetts Mental Health Center
 1976-1981 Member, Infections Committee, Massachusetts Mental Health Center
 1979-2003 Director of Psychopharmacology, Massachusetts Mental Health Center (closed in 2003)
 1979-2003 Chairman, Pharmacy & Therapeutics Committee
 1980-1981 President Medical Staff, Massachusetts Mental Health Center
 1986-1987 Chairman, 75th Anniversary Committee, Massachusetts Mental Health Center
 1991-2003 Chairman, Promotions Committee, Massachusetts Mental Health Center
 1991-2003 Director of Education, Massachusetts Mental Health Center

Other Professional Positions and Major Visiting Appointments

1967-1969 Research Psychiatrist, USPHS, NIMH, Program Director, Early Clinical Drug Evaluation Unit, Psychopharmacology Research Branch, NIMH
 1971 Advisor, Committee for a Sane Drug Policy Chestnut Hill, MA
 1976-1977 Consultant, Boston Institute for the Psychotherapies
 1979 Faculty, Staff College, National Institutes of Mental Health
 1982 Consortium Professor, Institute of Living and University of Connecticut
 1982 Boston University Department of Clinical Psychology, Instructor, PS 734, Psychopharmacology
 1990 The Asher Globus Visiting Professor of Psychiatry, Cornell University School of Medicine

1991 Visiting Associate Professor, UCLA Department of Psychiatry

Major Committee Assignments

National and Regional:

1972 Member, Commonwealth of Massachusetts Commissioner of Mental Health's Task Force on ECT

1976-1980 Examiner, American Board of Psychiatry and Neurology

1978 Chairman, Operations Committee, V.A. Cooperative Study of "Pharmacotherapy of Organic Brain Syndrome"

1978-1980 Member, Aging Review Panel, Center for Studies of the Mental Health of Aging, NIMH (Study Section)

1983 Chairman, Search Committee, for Commissioner of Mental Health, Department of Mental Health, Commonwealth of Massachusetts

1980-1987 American Board of Psychiatry and Neurology, Inc. Part I Examination Committee

1985-1988 Member, Treatment Development and Assessment Branch-2, NIMH (Study Section)

1985-1987 Co-Chairman, Credentials Committee, American College of Neuropsychopharmacology

1985-1988 Chairman, Consultation Committee American Psychiatric Association

1985- Member, Drugs and Therapeutics Committee, Massachusetts Medical Society

1985-1988 Member, American College of Psychiatry

1988- Member, Honorific Awards Committee, American College of Neuropsychopharmacology

1989- Fellow, American College of Psychiatry

1989- Chair, Massachusetts Psychiatric Society Nominating Committee

1986-1989 Chairman & Benzodiazepine Task Force, American Psychiatric Association; report author

1987-1988 Chairman, Treatment Development and Assessment Branch-2, NIMH (Study Section)

1989 Program Committee, New Clinical Drug Evaluation Unit, NIMH

1991- FDA Drug Advisory Committee: Medications Development Committee

1991- Program Committee, ACNP

1991- ACNP Review Committee, Dept. of Defense

1991- Chairman, American Psychiatric Association PIA Awards Committee

1991- NIH Consensus Conference: Depression in the Elderly

1992- Chairman, Dean Award Committee, American College of Psychiatrists

1994-	Psychopharmacology Advisory Committee, Food and Drug Administration
1990-	Psychoneurobiology Committee, World Psychiatric Association
1991-	Member, Task Force on Guidelines for Clinical Evaluation of Psychotropic Drugs, American College of Neuropsychopharmacology
1991-	Member, Psychiatric Diagnosis Committee, American Association for Geriatric Psychiatry
1991-	Chair, PIA Foundation Awards Board, American Psychiatric Association
1991-	Member, Psychoneurobiology Committee, World Psychiatric Association
1991-	Member, Academia, Medicina & Psychiatria Foundation
1992-	Fellow, Collegium Internationale Neuro-Psychopharmacologicum
1995-1998	Chair, Committee on the Dean Award, American College of Psychiatrists
1995-	Member, Society for Neuroscience
1996-	Fellow, American Psychopathological Association
2003-present	Distinguished Life Fellow, American Psychiatric Association
2004-	Massachusetts Psychiatric Society Nominating Committee

Harvard Medical School:

1978-	Committee on Aging
1982-	Ethel DuPont-Warren Award Committee
1984-1986	Human Studies Committee
1993-	Teacher-Clinician Promotion Committee
1994-	Ethics Advisory Committee
1998-2001	Promotions, Reappointments, and Appointments Committee
2001-	Subcommittee of Professors

Editorial Boards

1979	Journal of Partial Hospitalization
1982-	Contributing Editor, Hospital and Community Psychiatry (Psychopharmacology)
1984-1989	Harvard Medical School Mental Health Newsletter
1984-	Hospital and Community Psychiatry
1986-	Editorial Advisory Board, "Psychiatry" journal
1988-	Associate Editor, Psychopharmacology Bulletin
1989-	Journal of Geriatric Psychiatry and Neurology
1990-1993	Neuropsychopharmacology
1991-	Integrative Psychiatry
1991-	Journal of Gerontology
1992-	Assistant Editor, American Journal of Geriatric Psychiatry

1992-	Field Editor, Harvard Review of Psychiatry
1993-	Video Journal of Psychiatry
1994-1995	Contributing Editor, Practical Psychiatry and Behavioral Health
1996-2000	The American Journal of Psychiatry (editorial board)

Memberships, Offices and Committee Assignments in Professional Societies

1969	Massachusetts Medical Society
1969	Member, Social Issues Committee, Massachusetts Psychiatric Society
1970	Member, American Psychiatric Association
1971	Councilor, Northern New England Psychiatric Society, American Psychiatric Association
1973-1979	Scientific Associate, American College of Neuropsychopharmacology
1976	Fellow, American Psychiatric Association
1978	Member, Gerontological Society
1979	Chairman, Massachusetts Psychiatric Society Ad Hoc Task Force on Public Health Guidelines for Psychopharmacology
1979-	Member, American College of Neuropsychopharmacology
1979-1983	Chairman, Massachusetts Psychiatric Society Fellowship Committee
1979-1980	Member, Massachusetts Psychiatric Society Nominating Committee
1980-1982	Secretary, Massachusetts Psychiatric Society
1980-1982	Chairman, Ethics Committee, Massachusetts Psychiatric Society
1981-1984	Member, Education and Training Committee, American College of Neuropsychopharmacology
1982-1983	Member, Task Force of Psychotropic Drug Use in the Elderly, American Psychiatric Association
1982-1984	Co-Chairman, Legislative Committee, Massachusetts Psychiatric Society
1982-1983	President Elect, Massachusetts Psychiatric Society
1982-1984	Member, Nominating Committee, Massachusetts Psychiatric Society
1983-1984	President, Massachusetts Psychiatric Society
1983-1985	Member, Task Force on Anxiety Disorders, American Psychiatric Association
1984-1985	Immediate Past President, Massachusetts Psychiatric Society
1984-1985	Chairman, Constitution Committee, Massachusetts Psychiatric Society
1984-	Member, Boston Society for Gerontological Psychiatry
1989-	Long-Range Planning Committee, Massachusetts Psychiatric Society
2002	Life Fellow, American Psychiatric Association

2002 Life Fellow, American College of
Neuropsychopharmacology

Teaching Experience

Harvard Medical School:

1980-1986	Lecturer in Psychiatry 700b
1984-1988	Lecturer in Pharmacology 700b
1985-	Lecturer in Division on Aging
1989-1993	Psychiatry Faculty (Lecturer), New Pathway Curriculum (Neuroscience)
1990-1991	Lecturer, Pharmacy and Clinical Therapeutics Course (BCMP 501)

Other Institutions:

1977-	Assistant to Psychiatry Chief, Department of Medicine, Psychiatry Section, New England Deaconess Hospital. Visiting Psychopharmacology teaching at Cambridge Hospital.
1984-1987	Teaching at Harvard Community Health Plan
1985-1987	Teaching at Brockton VA Hospital, Department of Psychiatry
1991-	Teaching at MIT Health Service, Psychiatry Department

National Professional and Educational Leadership: Named Lectureships

Consortium Professor, Institute of Living and University of Connecticut, 1982.

Arthur Noyes Memorial Lecturer, 11/25/85, Norristown State Hospital.

Herman B. Dickel Memorial Lecturer, University of Oregon, 1/21/89.

The Asher Globus Visiting Professor of Psychiatry, Cornell University School of
Medicine, 1990.

Shih Yuan Tsai Memorial Lecture, UCLA West Los Angeles VA Medical Center,
11/1/93.

Awards

Elvin Semrad award for excellence in teaching, Massachusetts Mental Health
Center, 1984.

Vestermark Award, American Psychiatric Association, for Outstanding
Contribution to Psychiatric Education - awarded to American College of
Neuropsychopharmacology for model curriculum in Psychopharmacology, 1990

Honorable mention, Association for Academic Psychiatry Innovative Project in Psychiatric Education Award, 1991.

Voluntary/Part-Time Faculty Teacher of the Year: Payne Whitney Clinic, Cornell University School of Medicine, 1991

Heinz E. Lehmann Research Award, State of New York Office of Mental Health, for Outstanding Contributions to Research, 1997

United States Psychiatry Teacher of the Year Award, *Psychiatric Times*, 2003

Massachusetts Psychiatry Society
Outstanding Psychiatrist Award: Education, 2006

Massachusetts Psychiatric Society
Lifetime Achievement Award 2020

Harvard Medical School Department of Psychiatry
Stuart Hauser Award for Mentorship 2022.

Teacher of the Year Award, Longwood Psychiatry Residency Program 2009

Faculty Award for Excellence in Teaching and Mentorship, Beth Israel Deaconess Medical Center 2012

2014 Teacher of the Year Award, Mass Psychiatric Society

2020 Distinguished Lifetime Award, Mass Psychiatric Society

Current Research

2021: Committee on International Study of Psilocybin

2021: Committee on National Study of B-SNIP trial of clozapine in schizophrenia

Past funded research

Numerous studies of benzodiazepines;

Fluoxetine for borderline patients; paroxetine for depression

LSD in prison populations (NIMH);

Psilocybin in Theology student volunteers;

Marijuana effect on group decision making; studies of tetrahydrocannabinol;

Numerous clinical trials in geriatric subjects;

Studies of clozapine, aripiprazole, psychotic agitation

Publications

Original Articles

1. Salzman C, Shader RI, DiMascio A. Collagen disease-like syndrome following administration of a benzodiazepine derivative. *Diseases of the Nervous System* 1967;28:614-616.
2. DiMascio A, Shader RI, Salzman C, Harmatz J. An evaluation of isoquinazepon. *Current Therapy Research* 1967;9:38-45.
3. Gardos G, DiMascio A, Salzman C, Shader RI. Differential actions of chlordiazepoxide and oxazepam on hostility. *Archives of General Psychiatry* 1968;1:757-760.
4. Salzman C, DiMascio A, Shader RI, Harmatz J. Chlordiazepoxide, expectation and hostility. *Psychopharmacologia* 1969;14:38-45.
5. Ad Hoc Report Committee, Psychiatric Service. Psychiatric services to a sustained social protest campaign: An on-site, walk-in clinic at Resurrection City. *American Journal of Psychiatry* 1969;125:1543-1551.
6. Salzman C, Strauss ME, Engle RP, Kamins L. Overnight "guesting" of day hospital patients. *Comprehensive Psychiatry* 1969;10:369-375.
7. Waskow I, Olsson JE, Salzman C, Katz NM. Psychological effects of tetrahydrocannabinol. *Archives of General Psychiatry* 1970;22:97-107.
8. Shader RI, Salzman C, DiMascio A. Collagen disease-like reactions. In: RI Shader, A DiMascio, (eds). *Psychotropic Drug Side Effects*. Baltimore, MD: Williams and Wilkins 1970:261-279.
9. Salzman C, Shader RI, Pearlman M. Psychopharmacology and the elderly. In: RI Shader, A DiMascio, (eds). *Psychotropic Drug Side Effects*. Baltimore, MD: Williams and Wilkins 1970:261-279.
10. Salzman C, Shader RI, Scott DA, Binstock W. Interviewer anger and patient dropout in walk-in clinic. *Comprehensive Psychiatry* 1970;11:267-273.
11. Harmatz J, Shader RI, Salzman C. Marijuana users and non-users; personality test differences. *Archives of General Psychiatry* 1972;26:108-112.
12. Salzman C, Shader RI, Kochansky GE, Cronin DM. Rating scales for psychotropic drug research with geriatric patients. I. Behavior ratings. *Journal of the American Geriatric Society* 1972;20:209-214.

13. Salzman C, Kochansky GE, Shader RI, Cronin DM. Rating scales for psychotropic drug research with geriatric patients. II. Mood ratings. *Journal of the American Geriatric Society* 1972;20:215-221.
14. Salzman C, Lieff J, Kochansky GE, Shader RI. The psychology of hallucinogenic drug discontinuers. *American Journal of Psychiatry* 1972;129:755-761.
15. Reiss D, Salzman C. Resilience of family process: effect of secobarbital. *Archives of General Psychiatry* 1973;28:425-434.
16. Shader RI, Harmatz JS, Salzman C. A new scale for clinical assessment in geriatric populations: Sandoz clinical assessment-geriatric (SCAG). *Journal of the American Geriatric Society* 1974;22:107-113.
17. Chesson D, Geha DG, Salzman C. ECT, glaucoma and prolonged apnea. *Diseases of the Nervous System* 1974;35:152-153.
18. Salzman C, Hoffer A, Shader RI. Massachusetts psychiatrists trained at the Massachusetts Mental Health Center. *Mass. Journal of Mental Health* 1974;4:6-12.
19. Salzman C, Kochansky GE, Shader RI, Porrino LJ, Harmatz JS, Swett Jr. CP. Chlordiazepoxide-induced hostility in a small group setting. *Archives of General Psychiatry* 1974;31:401-405.
20. Salzman C, Lieff J. Interviews with hallucinogenic drug discontinuers. *Journal of Psychedelic Drugs* 1974;6:329-332.
21. Salzman C, Kochansky GE, Porrino LJ. Group Behavior: Hostility and Aggression. In: JH Mendelson, AM Rossi, RE Meyer, (eds). *The Use of Marijuana*. New York: Plenum Press 1974:73-80.
22. Kochansky GE, Hemenway III TS, Salzman C, Shader RI. Methaqualone abusers: A preliminary survey of college students. *Diseases of the Nervous System* 1975;36:348-371.
23. Kochansky GE, Salzman C, Shader RI, Harmatz JS, Ogletree AM. The differential effects of chlordiazepoxide and oxazepam upon hostility in a small group setting. *American Journal of Psychiatry* 1975;132:861-863.
24. Shader RI, Greenblatt DJ, Salzman C, Harmatz JS. Benzodiazepines: Safety and toxicity. *Diseases of the Nervous System* 1975;36:861-863.
24. Salzman C, Shader RI, Harmatz J, Robertson L. Psychopharmacologic investigations in elderly volunteers: effect of diazepam in males. *J Am Ger Soc* 1975;23:451-457.
26. Salzman C, Kochansky GE, Shader RI, Harmatz JS, Ogletree AM. Is oxazepam associated with hostility?. *Diseases of the Nervous System* 1975;36:30-32.

27. Salzman C, Shader RI, Harmatz JS. Response of the elderly to psychotropic drugs: Predictable or idiosyncratic? In: S Gershon, and A Raskin, (eds). *Aging*, Vol 2. New York: Raven Press 1975: 258-272.
28. Salzman C, Hoffer A, Shader RI. Alumni of the Massachusetts Mental Health Center residency training: public vs. private practice. *Archives of General Psychiatry* 1976;33:421-423.
29. Salzman C. Interpersonal problems in narcolepsy. *Psychosomatics* 1976;17:49-51.
30. Salzman C, van der Kolk BA, Shader RI. Marijuana and hostility in a small group setting. *American Journal of Psychiatry* 1976;133:1029-1033.
31. Salzman C, Shader RI. Responses to psychotropic drugs in the normal elderly. In: C Eisdorfer, WE Fann, (eds). *Psychopharmacology and Aging*. New York: Plenum Press, 1973:159-168.
32. Salzman C, Kochansky GE, van der Kolk BA, Shader RI. The effect of marijuana on small group process. *American Journal of Drug and Alcohol Abuse* 1977;4(2):251-255.
33. Kochansky GE, Salzman C, Shader RI, Harmatz JS, Ogletree AM. Effects of chlordiazepoxide and oxazepam administration on verbal hostility. *Archives of General Psychiatry* 1977;34:1457-1459.
34. Pildis M, Soverow G, Salzman C, Wolf J. Day hospital treatment of borderline patients; a clinical perspective. *American Journal of Psychiatry* 1978;135:594-596.
35. Ciraulo D, Lind L, Salzman C, Pilon R, Elkins R. Sodium nitroprusside in ECT-induced blood pressure elevations. *American Journal of Psychiatry* 1978;135:1105-1106.
36. Salzman C, van der Kolk BA. Psychotropic drugs and polypharmacy in elderly patients in a general hospital. *Journal of Geriatric Psychiatry* 1979;12:167-176.
37. Salzman C, van der Kolk BA. Psychotropic drug prescriptions for elderly patients in a general hospital. *Journal of the American Geriatric Society* 1980;28:18-22.
38. Salzman C. Psychotropic drug use and polypharmacy in a general hospital. *General Hospital Psychiatry* 1981;3:1-9.
39. Salzman C. Rating scales to study vasoactive drugs in the elderly. In: *Drugs and Methods in Cerebrovascular Disease: Proceedings of the International Symposium on Experimental Drugs and Methodologies for the Study of Acute and Chronic Diseases*. New York: Pergamon Press 1981:287-294.
40. Salzman C. Allocation of professional practice time. *Archives of General Psychiatry* 1982;39:489-490.

41. Salzman C, Shader RI, Greenblatt DJ, Harmatz JS. Long versus short half-life benzodiazepines in the elderly: Kinetics and clinical effects of diazepam and oxazepam. *Archives of General Psychiatry* 1983;40:293-297.
42. Mills MJ, Pearsall DT, Yesavage JA, Salzman C. Electroconvulsive therapy in Massachusetts. *American Journal of Psychiatry* 1984;141:534-538.
43. Salzman C, Green AI, Rodriguez-Villa F, Jaskiw GE. Benzodiazepines combined with neuroleptics for management of severe disruptive behavior. *Psychosomatics* 1986;27 (Suppl:17-21).
44. Salzman C, Bemporad J. Combined psychotherapeutic and psychopharmacologic treatment of depressed patients: Clinical observations. In: DW Manning, AJ Francis. *Combination Psychiatry and Psychotherapy in Depression*. APA Press 1990:152-181.
45. Green AI, Salzman C. Clozapine: Benefits and Risks. *Hospital and Community Psychiatry*, April 1990;41:379-380.
46. Salzman C. Notes from a State Mental Health Directors' Meeting on Clozapine. *Hospital and Community Psychiatry* 1990;41:838-840.
47. Salzman C. Mandatory Monitoring for Side Effects: The "Bundling of Clozapine." *N Eng J Med* 1990;323:827-829.
48. Salzman C, Solomon D, Miyawaki E, Glassman R, Rood L, Flowers E, Thayer S. Parenteral lorazepam vs. parenteral haloperidol for the control of psychotic disruptive behavior. *J Clin Psychiatry* 1991;52:177-180.
49. Salzman C, Fisher J, Nobel K, Glassman R, Wolfson A, Kelly M. Cognitive improvement following benzodiazepine discontinuation in elderly nursing home residents. *International Journal of Geriatric Psychiatry* 1992;7:89-93.
50. Glick, ID, Janowsky DS, Salzman C, Shader RI. A proposal for a model psychopharmacology curriculum for psychiatric residents. *Neuropsychopharmacology* 1993;8:1-5.
50. Green AI, Alam MY, Sobieraj JT, Pappalardo KM, Waternaux C, Salzman C, Schatzberg AF, and Schildkraut JJ. Clozapine response and plasma catecholamines and their metabolites. *Psychiatry Research* 1993;46:139-149.
52. Salzman JP, Salzman C, Wolfson AN, Albanese M, Looper J, Ostacher M, Schwartz J, Chinman G, Land W, Miyawaki E. Association between borderline personality structure and history of childhood abuse in adult volunteers. *Comprehensive Psychiatry* 1993;34:254-257.
53. Salzman C, Jimerson D, Vasile R, Watsky E, and Gerber J. Response to SSRI antidepressants correlates with reduction in plasma HVA: Pilot study. *Biol Psychiatry* 1993;34:569-571.

54. Green AI, Zalma A, Berman I, DuRand C, Salzman C. Clozapine following ECT: A two-step treatment. *J Clin Psychiatry* 1994;55:388-390.
55. Salzman C, Wolfson AN, Schatzberg A, et al. Effect of fluoxetine on anger in symptomatic volunteers with borderline personality disorder. *J Clin Psychopharmacology*, 1995;15:23-29.
56. Salzman C, Vaccaro B, Lieff J, et al. Clozapine in older patients with psychosis and behavioral disruption. *Am J Geriatric Psychiatry* 1995;3:26-33.
57. Longo LP, Salzman C. Valproic Acid Effects on Serum Concentrations of Clozapine and Norclozapine (Letter to the Editor). *Am J Psychiatry* 1995;152:650.
58. Burrows AB, Satlin A, Salzman C, et al. Depression in a long-term care facility: Clinical features and discordance between nursing assessment and patient interviews. *JAGS* 1995;43:1118-1122.
59. Salzman JP, Salzman C, Wolfson AN. Relationship of childhood abuse and maternal attachment to the development of borderline personality disorder. In: MC Zanarini, (ed). *The Role of Sexual Abuse in the Etiology of Borderline Personality Disorder*. Washington, American Psychiatric Association Press 1997, 71-91.
60. Fava M, Amsterdam JD, Delito JA, Salzman C, Schwaller M, and Dunner DL. A double-blind study of paroxetine, fluoxetine, and placebo in outpatients with major depression. *Annals of Clinical Psychiatry* 1998;10:145-150.
61. Yeung PP, Tariot PN, Schneider LS, Salzman C, and Rak IW. Quetiapine for elderly patients with psychotic disorders. *Psychiatric Annals* 2000;30:197-201.
62. Tariot PN, Salzman C, Yeung PP, Pultz J, and Rak IW. Long-term use of quetiapine in elderly patients with psychotic disorders. *Clinical Therapeutics* 2000;22:1068-1084.
63. Salzman C, Goldenberg I, Bruce SE, and Keller MB. Pharmacologic treatment of anxiety disorders in 1989 versus 1996: Results from the Harvard/Brown Anxiety Disorders Research Program. *J Clin Psychiatry* 2001;62:149-152.
64. Pace-Schott EF, Gersh T, Silvestri R, Stickgold R, Salzman C, and Hobson JA. SSRI treatment suppresses dream recall frequency but increases subjective dream intensity in normal subjects. *J Sleep Res* 2001;10:129-142.
65. Silvestri R, Pace-Shott EF, Gersh T, Stickgold R, Salzman C, Hobson JA. Effects of fluvoxamine and paroxetine on sleep structure in normal subjects: a home-based nightcap evaluation during drug administration and withdrawal. *J Clin Psychiatry* 2001;62:642-652.
66. Burrows AB, Salzman C, Satlin A, Noble K, Pollock BG, and Gersh T. A randomized, placebo-controlled trial of paroxetine in nursing home residents with non-major depression. *Depression and Anxiety* 2002;15:102-110.

67. Soumerai SB, Simoni-Wastila L, Singer C, Mah C, Gao X, Salzman C, Ross-Degnen. Lack of relationship between long-term use of benzodiazepines and escalation to high dosages. *Psychiatric Services* 2003;54:1006-1011.
68. Bruce SE, Vasile RG, Salzman C, Spencer M, Machan JT, Keller MB. Are benzodiazepines still the medication of choice for patients with panic disorder with or without agoraphobia. *Am J Psychiatry* 2003;160:1432-1438.
69. Roose SP, Nelson C, Salzman C, Hollander SB, Rodrigues H, and the Mirtazapine in the Nursing Home Study Group. Open-label study of mirtazapine orally disintegrating tablets in depressed patients in the nursing home. *Curr Med Res Opin* 2003;19:737-746.
70. Simoni-Wastila L, Ross-Degnan D, Mah C, Gao X, Brown J, Cosler LE, Fanning T, Gallagher P, Salzman C, Soumerai SB. A retrospective data analysis of the impact of the New York Triplicate Prescription Plan on benzodiazepine use in Medicaid patients with chronic psychiatric and neurologic disorders. *Clinical Therapeutics* 2004;26:322-336.
71. Ross-Degnan D, Simoni-Wastila L, Brown JS, Gao X, Mah C, Cosler LE, Fanning T, Gallagher P, Salzman C, Shader RI, Inui TS, and Soumerai SB. A controlled study of the effects of state surveillance on indicators of problematic and non-problematic benzodiazepine use in a Medicaid population. *Int'l J Psychiatry in Medicine* 2004;34:103-123.
72. Pearson SA, Soumerai S, Mah C, Zhang F, Simoni-Wastila L, Salzman C, Cosler LE, Fanning T, Gallagher P, Ross-Degnan D. Racial disparities in access after regulatory surveillance of benzodiazepines. *Arch Intern Med* 2006;166:572-579
73. Salzman C. Older drugs to treat anxiety and disordered sleep. *Primary Psychiatry* 2006;13(12):59-64
74. Salzman C. Schizophrenia symptoms remain stable during decreases from 2 antipsychotics to aripiprazole. *J Clin Psychiatry* 2007;68:970
75. Nelson JC, Holden K, Roose S, Salzman C, Hollander S. Are there predictors of poor outcome to mirtazapine orally disintegrating tablets in depressed elderly nursing home residents? *Int J Geriatric Psychiatry* 2007;22:999-1003.
76. Salzman C, Rosenberg J, Feldman JJ. Schizophrenia symptoms remain stable during decreases from 2 antipsychotics to aripiprazole. *J Clin Psychiatry* 2007;68(6):970
77. Meyer RE, Salzman C, Youngstrom EA, et al. Suicidality and Risk of Suicide—Definition, Drug Safety Concerns, and a Necessary Target for Drug Development: A brief Report. *J Clin Psychiatry* 2010; 71:1040-1025.
78. Meyer RE, Salzman C, Youngstrom EA, et al. Suicidality and Risk of Suicide—Definition, Drug Safety Concerns, and a Necessary Target for Drug Development: A Consensus Statement. *J Clin Psychiatry* 2010 (online).

79. Lu CY, Adams AS, Ross-Degnan D, Zhang F, Zhang Y, Salzman C, Soumerai SB. Association Between Prior Authorization for Medications and Health Service Use by Medicaid Patients with Bipolar Disorder. *Psychiatric Services* 2011; 62:186-193.

80. Abraham HD and Salzman C. Hallucinogen Persisting Perception Disorder Following Therapeutic Ketamine: A Case Report. *J Alcohol & Drug Dependence* 2017; 5:1-2.

Reviews and Chapters

1. Salzman C. Controlled therapy research with psychedelic drugs. In: PJ Fink, (ed). *A Critique in Psychedelic Drugs*. Baltimore, MD: Grune and Stratton 1969:23-32.
2. Salzman C, Kochansky GE, Shader RI. Rating scales for geriatric psychopharmacology: a review. *Psychopharmacology Bulletin* 1972;8:3-50.
3. Salzman C, Kochansky GE, Porrino L, Shader RI. Emotional side effects of placebo. In: RI Shader, (ed). *Psychiatric Complications of Medical Drugs*. New York: Raven Press 1972:369-387.
4. Salzman C, Shader RI. Research considerations in geriatric psychopharmacology. *Journal of Geriatric Psychiatry* 1974;7:165-184.
5. Salzman C, Shader RI. Methodology for the evaluation of psychotropic agents for geriatric patients. In: FG McMahon, (ed). *Principles and Techniques of Human Research and Therapeutics, Vol VIII Psychopharmacological agents*. Mt. Kisco, NY: Futura Publishing Co. 1974:145-155.
6. Salzman C. Psychopharmacology in the Aged. *J Geriat Psych* 1974;7 2:165-184.
7. Salzman C, Shader RI, Harmatz JS. Response of the Elderly to Psychotropic Drugs: Predictable or Idiosyncratic? In: S Gershon, A Raskin, (eds). *Aging Vol 2*. New York, Raven Press 1975:259-272
8. Salzman C. Electroconvulsive therapy. In: RI Shader, (ed). *A Manual of Psychiatric Therapeutics*. Boston, MA: Little, Brown and Co. 1975:115-124.
9. Salzman C, Shader RI, van der Kolk BA. Psychopharmacology and the geriatric patient. In: RI Shader, (ed). *A Manual of Psychiatric Therapeutics*. Boston, MA: Little, Brown and Co. 1975:171-184.
10. Salzman C, Shader RI, van der Kolk BA. Clinical psychopharmacology and the elderly patient. *New York State Journal of Medicine* 1976;76:71-77.
11. Salzman C. ECT and ethical psychiatry. *American Journal of Psychiatry* 1977;134:1006-1009.
12. Salzman C. Commentary on substance abuse and family interaction, paper by Klagsbrun M, Davis DI. *Family Process* 1977;16:149-164.
13. Salzman C. Electroconvulsive therapy. In: A Nicholi, (ed). *Harvard Guide to Modern Psychiatry*. Cambridge, MA: Harvard University Press 1978:471-479.
14. Salzman C. Social drugs: cannabis. In: MNG Dukes, (ed). *Side Effects of Drugs Annual 2*. Amsterdam: Excerpta Medica 1978:30-35.

15. Salzman C, Shader RI. Depression in the elderly: I. Relationship between depression, psychologic defense mechanisms and physical illness. *Journal of the American Geriatric Society* 1978;26:253-260.
16. Salzman C, Shader RI. Depression in the elderly: II. Possible drug etiologies; differential diagnostic criteria. *Journal of the American Geriatric Society* 1978;26:303-308.
17. Salzman C, Shader RI. Clinical evaluation of depression in the elderly. In: A Raskin, LF Jarvik, (eds). *Psychiatric Symptoms and Cognitive Loss in the Elderly*. Washington, DC: Hemisphere Publishers 1978:39-72.
18. Salzman C. Social drugs: cannabis. In: MNG Dukes, (ed). *Side Effects of Drugs Annual 3*. Amsterdam: Excerpta Medica 1979:26-28.
19. Salzman C. Update on geriatric psychopharmacology. *Geriatrics* 1979;34:87-90.
20. Salzman C. Polypharmacy and drug-drug interactions in the elderly. In: K Nandy, (ed). *Geriatric Psychopharmacology*. Elsevier, North Holland 1979:117-126.
21. Salzman C. Social drugs: cannabis. In: MNG Dukes, (ed). *Side Effects of Drugs Annual 4*. Amsterdam: Excerpta Medica 1980:26-28.
22. Salzman C. The use of ECT in the treatment of schizophrenia. *American Journal of Psychiatry* 1980;137:1032-1040.
23. Salzman C, Mirin S. Social drugs: cannabis. In: MNG Dukes, (ed). *Side Effects of Drugs Annual 5*. Amsterdam: Excerpta Medica 1981:28-32.
24. Salzman C. Antianxiety agents. In: T Crook, G Cohen, (eds). *Physicians' Handbook on Psychotherapeutic Drug Use in the Aged*. New Canaan, CT: Mark Powley Associates 1981:48-57.
25. Salzman C. Stimulants in the elderly. In: A Raskin, DS Robinson, J Levine, (eds). *Age and the Pharmacology of Psychoactive Drugs*. Cambridge, MA: Elsevier, North Holland 1981:171-180.
26. Salzman C. A primer on geriatric psychopharmacology. *American Journal of Psychiatry* 1982;139:67-74.
27. Salzman C. Management of Psychiatric Problems. In: JW Rowe, RW Besdine, (eds). *Health and Disease in Old Age*. Boston, MA: Little Brown 1982:115-135.
28. Salzman C. Basic principles of psychotropic drug prescription for the elderly. *Hospital and Community Psychiatry* 1982;33:133-136.
29. Salzman C. Social drugs: phencyclidine. In: MNG Dukes, (ed). *Side Effects of Drugs Annual 6*. Amsterdam: Excerpta Medica 1982:32-35.

30. Salzman C. Key concepts in geriatric psychopharmacology: Altered pharmacokinetics and polypharmacy. *Psychiatric Clinics of North America* 1982;5:181-190.
31. Salzman C. Electroconvulsive therapy in the elderly patient. *Psychiatric Clinics of North America* 1982;5:191-197.
32. Salzman C. Psychotropic drug side effects in the elderly. In: C Eisdorfer, WE Fann, (eds). *Treatment of psychopathology in the aging*. New York: Springer Publishing Company 1982:146-158.
33. Salzman C. Depression and physical disease. In: T Crook, G Cohen, (eds). *Physicians' Guide to the Diagnosis and Treatment of Depression in the Elderly*. New Canaan, CT: Mark Powley Associates 1983:9-17.
34. Salzman C, Green AI. Social drugs: phencyclidine. In: MNG Dukes, (ed). *Side Effects of Drugs Annual 7*. Amsterdam: Excerpta Medica 1983:38-42.
35. Salzman C, Hoffman SA, Schoonover SC. Geriatric psychopharmacology. In: EL Bassuk, SC Schoonover, A Gelenberg, (eds). *Practitioners' Guide to Psychoactive Drugs*. New York: Plenum Press 1983.
36. Salzman C, Hoffman SA. Clinical interaction between psychotropic and other drugs. *Hospital and Community Psychiatry* 1983;34:897-902.
37. Salzman C. The Sandoz clinical assessment-geriatric scale. In: T Crook, S Ferris, R Bartus, (eds). *Assessment in Geriatric Psychopharmacology*. New Canaan: Mark Powley Associates 1983:53-58.
38. Weinberger, DR, Salzman C. Brain imaging techniques and their usefulness in psychiatry. *Hospital & Community Psychiatry* 1984;35:325-326.
39. Salzman C, Green AI. Social drugs. In: MNG Dukes, (ed). *Side Effects of Drugs Annual 8*. Amsterdam: Excerpta Medica 1984:44-47.
40. Salzman C. Benzodiazepine habituation and withdrawal. *J Fam Pract Recertification* 1984: 6(suppl):39-47.
37. Ratey JJ, Salzman C. Recognizing and managing akathisia. *Hospital and Community Psychiatry* 1984;35:975-977.
42. Salzman C. Geriatric psychopharmacology. *Annual Review of Medicine* 1985;36:217-228.
43. Salzman C, Green AI. Social drugs: inhalants. In: MNG Dukes, (ed). *Side Effects of Drugs Annual 9*. Amsterdam: Excerpta Medica 1985: 33-38
44. Salzman C. Clinical use of antidepressant blood levels and the electrocardiogram. *New England Journal of Medicine* 1985;313:512-513 (editorial).

45. Salzman C. Clinical guidelines for the use of antidepressant drugs in geriatric patients. *J Clin Psychiatry* 1985;46:38-44.
46. Green AI, Salzman C. Social drugs: general. In: MNG Dukes, (ed). *Side Effects of Drugs Annual 10*. Amsterdam: Escerpta Medica 1986:34-39.
47. Salzman C, Gutfreund MJ. Clinical techniques and research strategies for studying depression and memory. In: LW Poon et al, (eds). *The handbook of Clinical Memory Assessment in the Elderly*. Washington, DC: American Psychological Association Press 1986:257-267.
48. Salzman C, Green AI. Differential therapeutics: Psychopharmacology. In: RE Hales, AJ Frances (eds). *Review of Psychiatry, Vol 6*. Washington, DC: American Psychiatric Press 1987:415-427.
49. Green AI, Salzman C. Social Drugs: general. In: MNG Dukes, (ed). *Side Effects of Drugs Annual 11*. Amsterdam: Excerpta Medica 1987:31-36.
50. Glassman R, Salzman C. Interactions between psychotropic and other drugs: An update. *Hospital and Community Psychiatry* 1987;38:236-242.
51. Salzman C. Treatment of the elderly agitated patient. *J Clin Psychiatry* 1987;48 (suppl):19-22.
52. Salzman C. Treatment of Agitation in the Elderly. In: *Psychopharmacology: The Third Generation of Progress*. HY Meltzer, (ed). New York, Raven Press 1987:1167-1176.
53. Salzman C. Treatment with antianxiety agents. In: TB Karasu, (ed). *Treatments of Psychiatric Disorders. A Task Force Report of the American Psychiatric Association*, Washington, DC. APPI 1989;184:2036-2052.
54. Rosebush P, Salzman C. Memory Disturbance and Cognitive Impairment in the Elderly. In: JP Tupin, RI Shader, DS Harnett, (eds). *Handbook of Clinical Psychopharmacology*, 2nd edition, New Northvale, New Jersey, London, Jason Aronson, Inc. 1988:159-210.
55. Salzman C. Treatment of the depressed elderly patient. In: HJ Altman, (ed). *Alzheimer's Disease and Dementia: Problems, Prospects and Perspectives*. New York, Plenum Press 1987:171-182.
56. Liptzin B, Salzman C. Psychiatric Aspects of Aging. In: JR Rowe, R Besdene, (eds). *Geriatric Medicine*, 2nd edition, Boston, MA: Little Brown 1988:355-374.
57. Berezin MA, Liptzin B, Salzman C. The Elderly Person. In: A Nicholi, (ed). *Harvard Guide to Modern Psychiatry*, 2nd edition. Cambridge, Harvard University Press 1988:665-680.

58. Salzman C. Treatment of agitation, anxiety, and depression in dementia. *Psychopharmacology Bulletin*. 1988;24:1 39-42.
59. Marcus L, Plasky P, Salzman C. Effects of psychotropic drugs on memory: part 1. *Hospital and Community Psychiatry*. March 1988;39:3 355-356.
60. Plasky P, Marcus L, Salzman C. Effects of psychotropic drugs on memory: part 2. *Hospital and Community Psychiatry*. May 1988; 39:501-502.
61. Salzman C. Benzodiazepines for the treatment of disorders other than anxiety and insomnia. *Advancement in Neurosciences* 1988;0:11-16.
62. Salzman C. Use of benzodiazepines to control disruptive behavior in inpatients. *J Clin Psychiatry* 1988;49:13-15.
63. Salzman C. Treatment of the agitated demented elderly patient. *Hospital and Community Psychiatry* 1988;39:1143-1144.
64. Green AI, Salzman C. Drugs of abuse: general. In: MNG Dukes, (ed). *Side Effects of Drug Annual 12*. Amsterdam: Excerpta Medica 1988:33-39.
65. Salzman C. Geriatric psychopharmacology. In: A Gelenberg, E Bassuk, S Schoonover. *The practitioner's Guide to Psychoactive Drugs*, 3rd edition. New York, Plenum Press 1991, pp 319-339.
66. Salzman C. Practical considerations on the pharmacologic treatment of depression and anxiety in the elderly. *J Clin Psychiatry* 1990;51:1(Suppl) 40-43.
67. Green AI, Bennet MB, Salzman C. An extramural training program in psychopharmacology: one model for a state system. *Hospital and Community Psychiatry* 1989;40:126-127.
68. Green AI, Salzman C. Drugs of abuse. In: MNG Dukes, (ed). *Side Effects of Drug Annual 13*. Amsterdam: Excerpta Medica 1989: 24-31.
69. Salzman C. Antidepressants. In: PF Lamy, (ed). *Clinics in Geriatric Medicine*, Philadelphia, Saunders 1990:399-410.
70. Salzman C. Principles of Psychopharmacology. In: DR Bienenfeld, (ed). *Verwoert's Clinical Geropsychiatry*. Baltimore, Williams and Wilkins 1990:234-249.
71. Salzman C. Recent advances in geriatric psychopharmacology. In: A Tasman, SM Goldfinger, CA Kaufman, (eds). *Review of Psychiatry, Vol 9*. Washington, DC: American Psychiatric Press 1990:279-292.
72. Salzman C. Neuropsychopharmacology. In: R Katzman, JR Rowe, (eds). *Principles of Geriatric Neurology*. Philadelphia, FA Davis Company 1992:59-72.

73. Salzman C. Pharmacologic Treatment of the Anxious Elderly Patient. In: C Salzman, B Lebowitz, (eds). *Anxiety in the Elderly*. New York, Springer. 1991:149-173.
74. Salzman C, Nevis-Olesen J. Psychopharmacologic Treatment. In: JE Birren, RB Sloane, GD Cohen (eds). *Handbook of Mental Health and Aging: Second Edition*. New York, Academic Press, Inc. 1992:721-762.
75. Green AI, Salzman C. Drugs of abuse. In: MNG Dukes, (ed). *Side Effects of Drug Annual 14*. Amsterdam: Excerpta Medica 1990:28-34.
76. Solomon DA, Miyawaki E, Salzman C. Benzodiazepine Augmentation of the Treatment of Disruptive Psychotic Behavior. In: EM Jucker, (ed). *Progress in Drug Research*. Basel, Switzerland: Birkhäuser Verlag. 1990:139-149.
77. Salzman C. Benzodiazepine Dependency. *Psychopharmacology Bull* 1990;26:61-62.
78. Salzman C. Editorial: The APA Task Force Report on Benzodiazepine Dependency, Toxicity, and Abuse. *American J Psychiatry*. 1991;148:151-152.
79. Salzman C. Anxiety Disorders. In: JC Beck, (ed). *Geriatrics Review Syllabus*. New York, American Geriatrics Society. 1991:241-246.
80. Salzman C. Benzodiazepines and Medical Practice. *Der Nervenarzt*. Berlin, Germany: Springer-Verlag 1991;62:61-63.
81. Salzman C. Behavioral Side Effects of Benzodiazepines. In: JM Kane, JA Lieberman, (eds). *Adverse Effects of Psychotropic Drugs*. New York, Guilford Press. 1992:139-162.
82. Watsky E, Salzman C. Psychotropic Drug Interactions. *Hospital and Community Psychiatry* 1991;42:247-256.
83. Salzman C, DuRand CJ. Pharmacological treatment of depression. In: JRM Copeland, MT Abou-Saleh, DG Blazer. *Principles and Practice of Geriatric Psychiatry*. Chichester, John Wiley & Sons, Ltd. 1994:575-580.
84. Salzman C, DuRand CJ. Anxiety and Phobic Disorders. In: JRM Copeland, MT Abou-Saleh, DG Blazer. *The Psychiatry of Old Age: An International Textbook*. London, John Wiley. In Press.
85. Salzman C. The American Psychiatric Association Task Force Report on Benzodiazepine Dependency, Toxicity, and Abuse. *J Psychiatric Research* 1990;24:1 (Suppl):35-37.
86. Salzman C. Anxiety in the Elderly: Treatment Strategies. *J Clin Psychiatry* 1990;51:10 (Suppl):18-21.

87. Salzman C, DuRand CJ. An overview of the treatment of geriatric disorders. In: DL Dunner, (ed). *Current Psychiatric Therapy*. Philadelphia, W.B. Saunders 1993:80-88.
88. Salzman C. Treatment of Anxiety. In: C Salzman, (ed). *Clinical Geriatric Psychopharmacology, Second Edition*. New York, Williams & Wilkins 1992:189-205.
89. Miyawaki E and Salzman C. Autonomic nervous system tests in psychiatry: Implications and potential uses of heart rate variability. *Integrative Psychiatry* 1991;7:21-28.
90. Salzman C. Why don't clinical trial results always correspond to clinical experience? *Neuropsychopharmacology* 1991;4:265-267.
91. Land W, Pinsky D, Salzman C. Abuse and misuse of anticholinergic medications. *Hospital and Community Psychiatry* 1991;42:580-581.
92. Salzman C. Benzodiazepine treatment of panic and agoraphobic symptoms: use, dependence, toxicity, and abuse. *J Psychiatric Research. J psychiat Res* 1993;27,Suppl 1:97-110.
93. Salzman C, Watsky E. Rational prescribing of benzodiazepines. In: C Hallström (ed). *Benzodiazepine Dependence*. New York: Oxford University Press, 1993:13-33.
94. Smith BD, Salzman C. Do benzodiazepines cause depression? *Hospital and Community Psychiatry* 1991;42:1101-1102.
95. Green AI, Watsky EJ, Salzman C. Drugs of abuse: Amphetamines. In: MNG Dukes, JK Aronson (eds). *Side Effects of Drugs Annual 15*. Amsterdam: Elsevier 1991:27-34.
96. Lamy PP, Salzman C, Nevis-Olesen J. Drug prescribing patterns, risks, and compliance guidelines. In: C Salzman, (ed). *Clinical Geriatric Psychopharmacology, Second Edition*. Williams & Wilkins 1992:15-32.
97. Lohr JB, Jeste DV, Harris M, Salzman C. Treatment of disordered behavior. In: C Salzman, (ed). *Clinical Geriatric Psychopharmacology, Second Edition*. Williams & Wilkins 1992:79-100.
98. Watsky E, Salzman C. Psychotropic drug dosages and drug interactions. In: C Salzman, (ed). *Clinical Geriatric Psychopharmacology, Second Edition*. Williams & Wilkins 1992:301-320.
99. Salzman C. Monoamine oxidase inhibitors and atypical antidepressants. *Clinics in Geriatric Medicine* 1992;8:335-348.
100. Berman I, Sapers BL, Salzman C. Sertraline: A new serotonergic antidepressant. *Hospital and Community Psychiatry* 1992;43:671-672.

101. Salzman C. The current status of fluoxetine (editorial). *Neuropsychopharmacology* 1992;7:245-247.
102. Wulson, LR, Frank E, Salzman C, Rush AJ, Jacobsberg L. Treatment selection in major depression. *The Journal of Psychotherapy Practice and Research* 1992;1:292-303.
103. Salzman, C. Pharmacological treatment of mood and anxiety disorders. *Psychiatria Hungarica* 1992;7:641-652.
104. Salzman C, Schneider LS, Lebowitz BD. Antidepressant treatment of very old patients. *American Journal of Geriatric Psychiatry* 1993;1:21-29.
105. Salzman C. Pharmacologic treatment of depression in the elderly. *J Clin Psychiatry* 1993;54:(suppl)23-28.
106. Green AI, Watsky EJ, Salzman C. Drugs of abuse: Amphetamines. In: MNG Dukes, JK Aronson (eds). *Side Effects of Drugs Annual 16*. Amsterdam: Elsevier 1993:22-28.
107. Salzman C. Emergency treatment of severe behavioral disruption. *Current Approaches to Psychoses* 1993;2:2,3,6.
108. Kingsbury SJ, Salzman C. Lithium's role in hyperparathyroidism and hypercalcemia. *Hospital & Community Psychiatry* 1993;44:1047-1048.
109. Salzman C, Miyawaki EK, Le Bars P, Kerrihard TN. Neurobiologic basis of anxiety and its treatment. *Harvard Rev Psychiatry* 1993;1:197-206.
110. Salzman C. Pharmacological treatment of depression in elderly patients. In: LS Schneider, CF Reynolds, BD Lebowitz, A Friedhoff (eds). *Diagnosis and Treatment of Depression in Late Life: Results of the NIH Consensus Development Conference*. American Psychiatric Press 1994, 181-244.
111. Land W, Salzman C. Risperidone: A novel anti-psychotic medication. *Hospital & Community Psychiatry* 1994;45:434-435.
112. Wong E, Salzman C, Green AI. Drugs of Abuse: Amphetamines. In: JK Aronson, CJ van Boxtel (eds). *Side Effects of Drugs Annual 17*. Amsterdam: Elsevier 1994:35-41.
113. Salzman C. Medication compliance in the elderly. *J Clin Psychiatry* 1995;56(suppl):18-22.
114. Dantzer A, Salzman C. Treatment of bipolar depression. *Psychiatric Services* 1995;46:229-230.
115. Salzman C, Satlin A, Burrows AB. Geriatric Psychopharmacology. In: AF Schatzberg and CB Nemeroff (eds). *Textbook of Psychopharmacology*. Washington, American Psychiatric Press 1995, 803-821.

116. Salzman C. Psychopharmacology. In: MH Sacks, WH Sledge, C Warren (eds). Core Readings in Psychiatry. Washington, American Psychiatric Press 1995, 461-482.
117. McDonald WM, Salzman C. Geriatric Psychopharmacology. In: R Michels, AM Cooper, et al (eds). Psychiatry, Revised Edition. Philadelphia, J.B. Lippincott, 1994 Vol.2, 1-23.
118. Salzman C, Schneider LS, Alexopoulos G. Pharmacological treatment of depression in late life. In: FE Bloom and DJ Kupfer (eds). Psychopharmacology: Fourth Generation of Progress. New York, Raven Press 1995, 1471-1477.
119. Salzman C. Farmakologiczne leczenie zaburze_nastriju i l_ku. In: Psychiatria America_ska Lat Dziewi__dzieai_tych, Collegium Medicum UJ Kraków 1995, 9-24.
120. Salzman C. Dealing with the sexual side effects of SSRI antidepressants. Jnl Prac Psych & Behav Hlth 1995;1:37-39.
121. Salzman C. Clinical use of nefazodone (Serzone). Jnl Prac Psych & Behav Hlth 1995;1:177-178.
122. Sheikh JI, and Salzman C. Anxiety in the elderly: Course and treatment. The Psychiatric Clinics of North America 1995;18:871-883.
123. Salzman C. Issues and controversies regarding benzodiazepine use. NIDA Research Monograph Series, 1993;131:68-89.
124. Salzman C. Treating the depressed artist. In: JJ Schildkraut & A Otero (eds). Depression and the Spiritual in Modern Art. New York, John Wiley & Sons 1996, 57-67.
125. Salzman C. Benzodiazepine dependence. In: R Michels, AM Cooper, SB Guze, et al. (eds). Psychiatry. Philadelphia, Lippincott-Raven 1995, Ch 115:1-7.
126. Salzman C. Heterogeneity of SSRI response. Harvard Rev Psychiatry, 1996;4:215-217.
127. Salzman C. The benzodiazepine controversy: therapeutic effects versus dependence, withdrawal, and toxicity. Harvard Rev Psychiatry 1997;4:279-282.
128. Patel JK, Salzman C, Green AI, et al. Chronic schizophrenia: response to clozapine, risperidone, and paroxetine. Am J Psychiatry 1997;154:543-546.
129. Fox HA, Salzman C. Resistant depression in the very old - A role for maintenance ECT? Harvard Rev Psychiatry 1995;3:152-155.
130. Salzman C. Update on the somatic treatment of depression in the older adult: psychopharmacology and ECT. Journal of Geriatric Psychiatry 1997;30:259-270.

131. Salzman C. ECT, research, and professional ambivalence (Editorial). *Am J Psychiatry* 1998;155:1-2.
132. Salzman C. Depressive disorders and other emotional issues in the elderly: current issues. *Int Clin Psychopharmacol* 1997;12(suppl 7):S37-S42.
133. Salzman C. Geriatric psychopharmacology. In: AJ Gelenberg and EL Bassuk. *The Practitioner's Guide to Psychoactive Drugs, Fourth Edition*. New York, Plenum 1998, 367-384.
134. Salzman C. St. John's Wort. *Harvard Rev Psychiatry* 1998;5:333-335.
135. Salzman C, and Freeman SA. Benefits versus risks of benzodiazepines. *Psychiatric Annals* 1998;28:139-141.
136. Salzman C. Integrating pharmacotherapy and psychotherapy in the treatment of a bipolar patient. *Am J Psychiatry* 1998;155:686-688.
137. Salzman C, Satlin A, and Burrows AB. Geriatric Psychopharmacology. In: AF Schatzberg and CB Nemeroff (eds). *The American Psychiatric Press Textbook of Psychopharmacology, Second Edition*. Washington, American Psychiatric Press 1998, 961-977.
138. Salzman C. Addiction to benzodiazepines. *Psychiatric Quarterly* 1998;69:251-261.
139. Salzman C. Treatment of the suicidal patient with psychotropic drugs and ECT. In: DG Jacobs (ed). *The Harvard Medical School Guide to Suicide Assessment and Intervention*. San Francisco, Jossey-Bass 1998, 372-382.
140. Jeste DV, Eastham JH, Lohr JB, Salzman C. Treatment of disordered behavior and psychosis. In: C Salzman (ed). *Clinical Geriatric Psychopharmacology, Third Edition*. Baltimore, Williams & Wilkins, 1998:106-149.
141. Jeste DV, Eastham JH, Lohr JB, Salzman C. Diagnosis of disordered behavior and psychosis. In: C Salzman (ed). *Clinical Geriatric Psychopharmacology, Third Edition*. Baltimore, Williams & Wilkins, 1998:97-105.
142. Alexopoulos GS, Salzman C. Treatment of depression with heterocyclic antidepressants, monoamine oxidase inhibitors, and psychomotor stimulants. In: C Salzman (ed). *Clinical Geriatric Psychopharmacology, Third Edition*. Baltimore, Williams & Wilkins, 1998:184-244.
143. Small GW, and Salzman C. Treatment of depression with new and atypical antidepressants. In: C Salzman (ed). *Clinical Geriatric Psychopharmacology, Third Edition*. Baltimore, Williams & Wilkins, 1998:245-261.

144. Salzman C. Treatment of anxiety and anxiety-related disorders. In: C Salzman (ed). *Clinical Geriatric Psychopharmacology*, Third Edition. Baltimore, Williams & Wilkins, 1998:343-368.
145. Salzman C, Sheikh JI. Diagnosis of anxiety and anxiety-related disorders. In: C Salzman (ed). *Clinical Geriatric Psychopharmacology*, Third Edition. Baltimore, Williams & Wilkins, 1998:245-261.
146. Salzman C. An 87-year-old woman taking a benzodiazepine. *JAMA* 1999;281:1121-1125.
147. Salzman C. Effects of psychotropic medications on pancreatic function: A review. *Harvard Review of Psychiatry* 1999;7:54-60.
148. Salzman C. Not all psychiatric research is bad! (Editorial). *Am J Psychiatry* 1999;156:987-988.
149. Salzman C. Practical considerations for treatment of depression in elderly and very elderly long-term care patients. *J Clin Psychiatry* 1999;60 (suppl 20):30-33.
150. Yeung PP, Tariot PN, Schneider LS, Salzman C, Rak IW. Quetiapine for elderly patients with psychotic disorders. *Psychiatric Annals* 2000;30:197-201.
151. Echols JC, Naidoo U, Salzman C. SAME (adenosylmethionine). *Harvard Rev Psychiatry* 2000;8:84-93.
152. Salzman C. Mood disorders. In: CE Coffey, JL Cummings (eds). *The American Textbook of Geriatric Neuropsychiatry*, Second Edition. Washington, American Psychiatric Press, 2000:313-328.
153. Salzman C. Treatment of the agitation of late-life psychosis and Alzheimer's disease. *Eur Psychiatry* 2000;15 Suppl 3:1-4.
154. Salzman C. Introduction to Special Issue: Schizophrenia in Late Life. *Harvard Rev Psychiatry* 2001;9 (March/April):49-50.
155. Salzman C and Tune L. Neuroleptic treatment of late-life schizophrenia. *Harvard Rev Psychiatry* 2001;9 (March/April):77-83.
156. Salzman C. Management considerations for late-life depression. *J Clin Psychiatry* 2000;2(suppl 5):33-36.
157. Salzman C, Satlin A, and Burrows AB. Geriatric Psychopharmacology. In: AF Schatzberg, CB Nemeroff (eds). *Essentials of Clinical Psychopharmacology*. Washington, American Psychiatric Press 2001:637-658 .

158. Salzman C. Interpersonal problems in bipolar disorder and their psychotherapeutic treatment. In: M Maj, HS Akiskal, JJ Lopez-Ibor, N Sartorius (eds). *Bipolar Disorder*. Chichester UK, John Wiley & Sons 2002:353-355.
159. Salzman C, Wong E, and Wright BC. Treatment of depression in the elderly, 1996-2001: A literature review. *Biol Psychiatry* 2002;52:265-284.
160. McDonald WM, Salzman C, and Schatzberg AF. Depression in the elderly. *Psychopharm Bull* 2002;36(Suppl 2):112-122.
161. Tune LE and Salzman C. Schizophrenia in late life. *Psychiatric Clinics of North America* 2003;26:103-113.
162. Charney DS, Reynolds CF III, Lewis L, et al. Depression and Bipolar Support Alliance Consensus Statement on the Unmet Needs in Diagnosis and Treatment of Mood Disorders in Late Life. *Arch Gen Psychiatry* 2003;60:664-672.
163. Salzman C. New uses for lithium and anticonvulsants. *Harv Rev Psychiatry* 2003;11:230-244.
164. Bruce SE, Vasile RG, Goisman RM, Salzman C et al; Are Medications Still the Treatment of Choice for Patients with Panic Disorder With or Without Agoraphobia? 2003, *Am J Psychiatry* 160:1432-1438.
165. Soumerai SB, Simoni-Wastila L, Singer C, Mah C, Gao X, Salzman C, Ross-Degnan D. Lack of Relationship Between Long-Term Use of benzodiazepine and Escalation in High Dose? ; *Psychiatric Services* 2003, 54:1006-1011.
166. Salzman C. Foreword. In: J Lokvig, JD Becker. *Alzheimer's A to Z: A Quick Reference Guide*. Oakland, New Harbinger, 2004:ix-x.
167. Salzman C. Treatment of anxiety and anxiety-related disorder. In: C Salzman, (ed). *Clinical Geriatric Psychopharmacology, Fourth Edition*. Philadelphia, Lippincott Williams & Wilkins, 2005:449-479.
168. Salzman C. Appendix A. Prescribing information. In: C Salzman, (ed). *Clinical Geriatric Psychopharmacology, Fourth Edition*. Philadelphia, Lippincott Williams & Wilkins, 2005:625-629.
169. Salzman C, Small GW. Treatment of depression with new and atypical antidepressants. In: C Salzman, (ed). *Clinical Geriatric Psychopharmacology, Fourth Edition*. Philadelphia, Lippincott Williams & Wilkins, 2005:305-333.
170. Salzman C, Roose SP, Chatterjee A. Treatment of late-life depression associated with medical illness. In: C Salzman, (ed). *Clinical Geriatric Psychopharmacology, Fourth Edition*. Philadelphia, Lippincott Williams & Wilkins, 2005:335-351.

171. Salzman C, Sheikh JI. Diagnosis of anxiety and anxiety-related disorders. In: C Salzman, (ed). *Clinical Geriatric Psychopharmacology*, Fourth Edition. Philadelphia, Lippincott Williams & Wilkins, 2005:437-448.
172. Jeste DV, Sable JA, Salzman C. Treatment of late-life disordered behavior, agitation, and psychosis. In: C Salzman, (ed). *Clinical Geriatric Psychopharmacology*, Fourth Edition. Philadelphia, Lippincott Williams & Wilkins, 2005:129-195.
- 173 . Alexopoulos GS, Lerner DM, Salzman C. Treatment of depression with tricyclic antidepressants, monoamine oxidase inhibitors, and psychostimulants. In: C Salzman, (ed). *Clinical Geriatric Psychopharmacology*, Fourth Edition. Philadelphia, Lippincott Williams & Wilkins, 2005:233-303.
174. Alexopoulos GS, Lerner DM, Salzman C. Response prediction, maintenance treatment, and late-life depression. In: C Salzman, (ed). *Clinical Geriatric Psychopharmacology*, Fourth Edition. Philadelphia, Lippincott Williams & Wilkins, 2005:423-434.
175. Jeste DV, Sable JA, Salzman C. Diagnosis of late-life disordered behavior, agitation, and psychosis. In: C Salzman, (ed). *Clinical Geriatric Psychopharmacology*, Fourth Edition. Philadelphia, Lippincott Williams & Wilkins, 2005:117-127.
176. Schneider L, Tariot P, Salzman C. Treatment of dementia. In: C Salzman, (ed). *Clinical Geriatric Psychopharmacology*, Fourth Edition. Philadelphia, Lippincott Williams & Wilkins, 2005:595-623.
177. Wiersgalla M, Salzman C. Appendix B. Enzyme metabolism and drug interaction. In: C Salzman, (ed). *Clinical Geriatric Psychopharmacology*, Fourth Edition. Philadelphia, Lippincott Williams & Wilkins, 2005:631-641.
178. Wiersgalla M, Salzman C. Appendix C. Drug interactions with psychotropic medications. In: C Salzman, (ed). *Clinical Geriatric Psychopharmacology*, Fourth Edition. Philadelphia, Lippincott Williams & Wilkins, 2005:643-676.
179. Salzman C. The rise of geriatric psychopharmacology. In: TA Ban, D Healy, E Shorter, (eds). *Reflections on Twentieth-Century Psychopharmacology*, Animula, Budapest, Hungary, 2004:690-696.
180. Salzman C. Late-life anxiety disorders. *Psychopharm Bull* 2004;38(suppl 1):25-30.
181. Salzman C. The limited role of expert guidelines in teaching psychopharmacology. *Academic Psychiatry*, 2005;29:176-179
182. Salzman C. Antidepressants and mood stabilizers. In: BJ Sadock and VA Sadock (eds). *Comprehensive Textbook of Psychiatry*. Baltimore, Williams & Wilkins, 2005:3720-3724

183. Brooke NS, Wiersgalla M, Salzman M. Atypical uses of atypical antipsychotics. *Harv Rev Psychiatry* 2005;13:317-339
184. Salzman C. Antidepressants and mood stabilizers. In: BJ Sadock and VA Sadock (eds). *Comprehensive Textbook of Psychiatry*. Baltimore, Williams & Wilkins, 2005:3720-3724
185. Jeste D, Dolder CR, Nayak GV, Salzman C. Atypical Antipsychotics in elderly patients with dementia of schizophrenia: review of recent literature. *Harv Rev Psychiatry* 2005;13:340-351
186. Salzman C. Withdrawal syndrome: Description and treatment, benzodiazepines. In: J Jaffe (ed). *Encyclopedia of Drugs and Alcohol*. Macmillan, In Press.
187. Glick ID, Salzman C, Cohen BM, Klein DF, Moutier C, Nasrallah HA, Ongur D, Wang P, Zisook S. Improving the pedagogy associated with the teaching of psychopharmacology. *Academic Psychiatry* 2007;31:211-217
188. Jeste DV, Blazer D, Casey D, Meeks T, Salzman C, Schneider L, Tariot P, Yaffe C. ACNP White Paper on the use of antipsychotic drugs in elderly persons with dementia: an update* *Neuropsychopharm* 2008;33(5):957-70
189. Salzman C, Tariot P. Treatment of agitation and aggression in the elderly. In: APPI *Textbook of Psychopharmacology, Fourth Edition* 2007
190. Salzman C. Psychopharmacology: Antidepressants and mood stabilizer (Geriatric Psychiatry). *Comprehensive Textbook of Psychiatry, 9th Edition* 2007; 4105-4109
191. Zisook et al. Teaching Psychopharmacology: What works and what doesn't. *J Clin Psychopharmacology* 2008;28(1):96-100.
192. Rosenberg J, Salzman C. Update: New Uses for Lithium and Anticonvulsants. *CNS Drugs* 2007;12(11):831-841
193. Ancoli-Israel S, Ayalon L, Salzman C. Sleep in the Elderly: Normal Variations and Common Sleep Disorders. *Har Rev Psychiatry* 2008;16:279-286
194. Salzman C, Jeste DV, Meyer RE, Cohen-Mansfield J, Cummings J, Grossberg GT, Jarvik L, Kraemer HC, et al. Elderly patients with dementia-related symptoms of severe agitation and aggression: consensus statement on treatment options, clinical trials methodology, and policy *J Clin Psychiatry* 2008;69:889-898
195. Salzman C. Pharmacologic Treatment of Disturbed Sleep in the Elderly. *Harv Rev Psychiatry* 2008;16:271-278
196. Salzman C. Antidepressants and Mood Stabilizers. In: *Comprehensive Textbook of Psychiatry, 9th Edition*. Eds: Sadock BJ, Sadock VA, Ruiz P. 2009;4105-4109

197. Ellison JM, Sivrioglu EY, Salzman C. "Pharmacotherapy of Late-Life Depression Evidence-Based Recommendations." Eds. Ellison JM, Kyomen HH, Verma S. Mood Disorders in Later Life, Second Edition. New York, Informa Healthcare USA, Inc, 2009
198. Salzman C and Tariot PN. "Treatment of Agitation and Aggression in the Elderly." Eds. Schatzberg AF, Nemeroff CB. Textbook of Psychopharmacology, Fourth Edition. Virginia, American Psychiatric Publishing, Inc, 2009 pp.1201-1212.
199. Salzman C. What is a Geriatric Psychopharmacologist to Do? 2010, J Clin Psychopharmacology 485-486 (editorial).
200. Salzman C., Glick I, Keshavan MS. The 7 Sins of Psychopharmacology. 2010, J Clin Psychopharmacology 30:653-655 (editorial).
201. Salzman C, Mooney JJ: Brain volume decline in first-episode schizophrenics (letter to the editor). Arch Gen Psychiat (electronic), March 4, 2011.
202. Salzman C. In Memorium Alexander (Sandy) H. Glassman MD. J Clin Psychopharm 31:688-689.
203. Salzman C. Antipsychotic Drugs in Nursing Homes (editorial). J Clin Psychopharm, in press.
204. Salzman C, Shader RI. Benzodiazepine Use and Risk for Alzheimer Disease. 2015, J Clin Psychopharmacology 35:1-3 (editorial).
205. Salzman C, Glick ID. Teaching the Teachers of Clinical Psychopharmacology 2015; Academic Psychiatry 39:475-481.
206. Salzman C. Late-Life Depression and Antidepressants. 2015: American J Geriat Psychiatry
- 207: Salzman C. Treatment of Agitation and Aggression in the Elderly. IN: A Schatzberg, C Nemeroff, (eds). American Psychiatric Publishing Textbook of Psychiatry, Fifth edition, 2015.
208. Salzman C. Antidepressants and Mood Stabilizers. IN: Comprehensive Textbook of Psychiatry, 9^{10h} Edition. Eds: Sadock BJ, Sadock VA, Ruiz P. 2015.
209. Salzman C, Shader RI. Not Again: Benzodiazepines Once More Under Attack. 2015, J Clin Psychopharmacology, 2015; 35:493-495.
210. Salzman C. Treatment of Agitation and Aggression in the Elderly. IN: AF Schatzberg & CB Nemeroff: APA Textbook of Psychopharmacology Fifth Edition Washington, APA Press pp 1623-1630.

211. Salzman C. Antidepressants and mood stabilizers. In: BJ Sadock and VA Sadock (eds). *Comprehensive Textbook of Psychiatry*. Baltimore, Williams & Wilkins, 2017:4123-4127.
212. Salzman C: Treat the Patient, Not the Rule Book...: The Art of Psychopharmacology! *The Journal of Nervous and Mental Disease*: May 2018 - Volume 206 - Issue 5 - p 380–382
213. Salzman C & multiple authors: The Prescription of Benzodiazepines for Panic Disorder: Time for an Evidence-Based Educational Approach; *J Clinical Psychopharmacology* 2018, 38:283,
214. Balon R, Salzman C and Multiple authors; International Task Force on Benzodiazepines; *Psychotherapy Psychosomatics* 2018; DOI:10.1159/000489538.
215. Abraham HD, Salzman C; Hallucinogen Persisting Perception Disorder Following Therapeutic Ketamine: A Case Report; *J Alcohol Drug Depend* 2017; 5:5,
216. Salzman C. Do benzodiazepines cause Alzheimer’s Disease? *Am J Psychiatry* 2020;177:476-478.
217. Salzman C. Treating Agitated Demented Patients is Not Easy and is Not Cheap. *International Psychogeriatrics*, Volume 34, Special Issue 10: Issue Theme: Pharmacotherapy for Serious Neuropsychiatric Disorders , October 2022 , pp. 865 – 866.

Lay Publications

Salzman C. “How to help anxious minds.” *Newsweek*. September 22, 2008. p. 67

Books

1. Salzman C. *Clinical Geriatric Psychopharmacology*. New York, McGraw-Hill, 1984.
2. Glick I, Janowsky D, Salzman C, Shader R. *A Model Psychopharmacology Curriculum for Psychiatric resident*. Ad Hoc Committee of the American College of Neuropsychopharmacology, 1984.
3. Salzman C, Lebowitz B, (eds). *Anxiety in the Elderly*. New York, Springer, 1991.
4. Salzman C, et al. *Benzodiazepine Dependence, Toxicity, and Abuse: A Task Force Report of the American Psychiatric Association*. Washington, American Psychiatric Press, 1990.
5. Salzman C. *Clinical Geriatric Psychopharmacology, Second Edition*. Baltimore, Williams & Wilkins, 1992.

6. Salzman C, (ed). Clinical Geriatric Psychopharmacology, Third Edition. Baltimore, Williams & Wilkins, 1998.
7. Salzman C. Psychiatric Medications for Older Adults. New York, Guilford, 2001.
8. Salzman C, (ed). Clinical Geriatric Psychopharmacology, Fourth Edition. Philadelphia, Lippincott Williams & Wilkins, 2005.
9. Salzman C (ed): AN ORAL AN ORAL HISTORY OF NEUROPSYCHOPHARMACOLOGY: PEER INTERVIEWS; Volume 8. Diverse Topics 2012; American College of Neuropsychopharmacology (publisher).